Allergy
Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
[corrected-article]
Jae-Woo Jung, Hae-Sim Park, Choon-Sik Park, Sang-Heon Cho, Inseon S. Choi, Hee-Bom Moon, Soon Seog Kwon, Ho Joo Yoon, Jung Won Park, Jong-Myung Lee, Dong-Chull Choi, Byoung Whui Choi
Korean J Intern Med. 2021;36(4):1001-1013. Published online June 1, 2021
Background/Aims: Omalizumab is the first biologic known to be effective in patients with severe allergic asthma.
Methods: This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 w..
|